Tempest Therapeutics (TPST) Accounts Payables (2011 - 2026)

Tempest Therapeutics has disclosed Accounts Payables across 16 years of filings, most recently posting $2.0 million for Q2 2026.

• In Q2 2026, Accounts Payables fell 57.7% year-over-year to $2.0 million; the TTM figure through Jun 2026 stood at $2.0 million (down 57.7% YoY), while the FY2025 annual figure was $1.0 million, down 57.63% from the prior year.
• Accounts Payables came in at $2.0 million for Q2 2026 at Tempest Therapeutics, up from $1.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.7 million in Q2 2025 to a low of $684000.0 in Q1 2022.
• Average Accounts Payables over 5 years is $1.5 million, with a median of $1.1 million recorded in 2023.
• Year-over-year, Accounts Payables slumped 78.37% in 2022 and surged 247.53% in 2025.
• Over 5 years, Accounts Payables stood at $1.1 million in 2022, then retreated by 23.74% to $845000.0 in 2023, then surged by 189.94% to $2.4 million in 2024, then tumbled by 57.63% to $1.0 million in 2025, then soared by 92.2% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.0 million in Q2 2026, $1.0 million in Q4 2025, and $922000.0 in Q3 2025.